title: [Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].
abstract: The translation of quantitative polymerase chain reaction technology for the quantitative detection of minimal residual disease (MRD) arising from molecular aberrations in leukaemias has progressed from the pre-clinical setting to daily clinical practice. Thus, it is now part of the mainstay in following patients with chronic myeloid leukaemia treated with the tyrosine kinase inhibitor imatinib. Moreover, the methodology is being integrated in an increasing number of clinical trials, where it is expected to result in more rational and individualized clinical decision-making. A special point in favour of the techniques is the powerful and early detection of disease relapses, in some cases up to one year prior to clinical detection.
authors.affiliation: Immunhaematologisk Laboratorium, Haematologisk Afdeling R, Arhus Universitetshospital, Arhus Sygehus, DK-8000 Arhus C. phokland@ki.au.dk
authors.forename: Peter
authors.initials: P
authors.lastname: Hokland
authors.forename: Hans Beier
authors.initials: HB
authors.lastname: Ommen
authors.forename: Charlotte Guldborg
authors.initials: CG
authors.lastname: Nyvold
authors.forename: Jesper
authors.initials: J
authors.lastname: Stentoft
authors.forename: Karin
authors.initials: K
authors.lastname: Braendstrup
authors.forename: Bodil Lind
authors.initials: BL
authors.lastname: Andersen
authors.forename: Lone Siig
authors.initials: LS
authors.lastname: Mikkelsen
authors.forename: Mette
authors.initials: M
authors.lastname: Ostergaard
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000032:analysis; D055088:Early Detection of Cancer; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000235:genetics; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate